4d agoThe FlyBEARISH 18General
Archived explainer. For the current picture see today's IONS page.
Why Is IONIS PHARMACEUTICAL (IONS) Stock Down Today?
By the Top Tier Newswire AI Desk · November 9, 2026 at 2:16 PM ET · reviewed against 17 wire stories
IONIS PHARMACEUTICAL (IONS) is down -23.08% in the latest session. Our newswire has captured 17 stories on IONS across 10 sources in the last 36 hours, with AI sentiment reading bearish (avg 39/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Ionis Pharmaceuticals shares fell 23.08% to close at $30.32 on Monday. The sharp decline followed the company’s release of third-quarter 2026 financial results, which included a significant reduction in sales guidance for its lead product, Tryngolza.
What Happened
Ionis reported Q3 2026 revenue of $243 million, a 55% increase year over year. The company posted a loss of $0.66 per share, beating expectations on both the top and bottom lines. Despite the earnings beat, management cut the 2026 sales guidance for Tryngolza to $50 million. The company maintained its full-year financial outlook. Kehoe Law Firm, P.C. announced it is investigating potential securities claims on behalf of investors following the guidance cut and subsequent stock decline.
What The Data Shows
The stock opened at $37.00, a 6.1% gap down from the prior close of $39.42. Trading volume reached 11.0 million shares, which is 3.1 times the three-month daily average. The session low was $27.75 at 10:10 AM ET. Ionis has a market capitalization of $6.6 billion and is currently unprofitable with a trailing twelve-month EPS of -$3.46. The stock is trading near its 52-week low, with a range of $38.30 to $86.74. Over the last 8 sessions, the stock declined 12.2% from $44.90 to $39.42. Recent insider activity includes two sales totaling $61,000 by EVPs Shannon L. Devers and Eric Swayze in mid-October.
What To Watch
Investors will monitor the company’s response to the lowered Tryngolza outlook and any further developments in the securities investigation.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IONS by the numbers
Last: $30.32Session: -23.08%7 sessions: -30.16%Coverage: 17 stories / 10 sourcesAI sentiment: 39/100 (bearish)Mkt cap: $6.6B52w: $38.30 to $86.74
The headlines behind the move
4d agoGuruFocusBEARISH 24Earnings
Ionis Pharmaceuticals (IONS) Shares Drop 27% After Lowered Tryngolza Revenue Forecast
4d agoGuruFocusBEARISH 34Earnings
Ionis Pharma Faces Pressure After Q3 Results and Reduced TRYNGOLZA Sales Outlook
4d agoInvestorsHubBEARISH 42Earnings
Ionis Pharmaceuticals Reports 55% Rise in Q3 Revenue to $243 Million, Cuts TRYNGOLZA Sales Guidance
Ionis Pharmaceuticals reports Q3 2026 revenue of $243 million, cuts TRYNGOLZA sales guidance to $50 million and maintains its full-year financial outlook.
4d agoSeeking AlphaBEARISH 31Earnings
Ionis plummets as it cuts 2026 revenue guidance for Tryngolza
Ionis stock sank after Tryngolza sales guidance was slashed despite a Q3 earnings beat.
4d agoBriefing.comBEARISH 34Earnings
Ionis Pharma Plummets as TRYNGOLZA Guidance Cut Overshadows Q3 Beat (IONS)
Ionis Pharma (IONS) is under heavy pressure today following its Q3 results. While the company beat expectations on the top and bottom lines, reporting a loss of $0.66 per share on revenue of $243 mln, up 55% yr/yr, and reaffirmed its overall FY26 revenue guidance of $875-900 mln, it sharply reduced its expectations for TRYNGOLZA sales. Specifically, IONS now expects approximately $50 mln in FY26 sales, down from its prior outlook of $100-110 mln, reflecting a slower-than-anticipated launch…
4d agoGlobeNewswireBEARISH 34General
Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating
Kehoe Law Firm investigating potential securities claims on behalf of Ionis (IONS) investors following reduced TRYNGOLZA sales guidance and stock decline...
4d agoThe FlyBEARISH 22General
Ionis Pharmaceuticals falls -27.0%
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IONS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IONS move explainers: 2026-11-10 · 2026-11-09 · 2026-09-15 · 2026-09-08 · 2026-09-03 · 2026-07-11